Lisata Therapeutics adds Jeffrey Farrow to its board of directors

Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the appointment of Jeffrey Farrow to its board of directors, effective October 13, 2026, expanding the board from seven to eight members.

Farrow fills a newly created Class III director seat, appointed upon the recommendation of the Nominating and Corporate Governance Committee. He will also serve on the Audit Committee. The board has determined that Farrow qualifies as independent under Nasdaq listing rules.

Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS). He also sits on the boards of Clover Biopharmaceuticals, Ltd. (HKEX) and Achieve Life Sciences, Inc. (Nasdaq: ACHV), where he chairs the audit committee.

From 2016 to 2022, Farrow was CFO of Global Blood Therapeutics, Inc. through its acquisition by Pfizer Inc. He previously served as CFO of ZS Pharma, Inc. through its acquisition by AstraZeneca in 2015, and as CFO of Hyperion Therapeutics, Inc. through its acquisition by Horizon Therapeutics in 2015. Earlier roles included finance leadership positions at Evotec AG and Renovis, Inc. He began his career with seven years in the audit practice of KPMG LLP.

Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University, Fullerton, and is a certified public accountant (inactive).

Lisata is a clinical-stage pharmaceutical company with Phase 2b programs in severe hypertriglyceridemia and acromegaly, according to a company press release.

You May Also Be Interested In

• Deckers Brands names RealReal CEO to its board of directors
• Gilead to buy oral IBD drug candidate for $1.275 billion
• Atlantic American faces Nasdaq delisting over late SEC filings